Home/Filings/4/0001209191-19-002778
4//SEC Filing

Cooper Laurence James Neil 4

Accession 0001209191-19-002778

CIK 0001107421other

Filed

Jan 7, 7:00 PM ET

Accepted

Jan 8, 4:24 PM ET

Size

10.7 KB

Accession

0001209191-19-002778

Insider Transaction Report

Form 4
Period: 2019-01-06
Cooper Laurence James Neil
Chief Executive Officer
Transactions
  • Award

    Common Stock

    2019-01-06+446,4281,964,503 total
  • Award

    Employee Stock Option (right to buy)

    2019-01-06+531,813531,813 total
    Exercise: $2.24Exp: 2029-01-06Common Stock (531,813 underlying)
  • Award

    Common Stock

    2019-01-06+337,2661,518,075 total
  • Tax Payment

    Common Stock

    2019-01-06$2.24/sh165,178$369,9991,799,325 total
Footnotes (4)
  • [F1]112,422 shares shall vest on each of 12/31/2019, 12/31/2020 and 12/31/2021.
  • [F2]Pursuant to the Issuer's option plan, the Reporting Person elected to receive fully vested shares of Common Stock in lieu of a cash bonus.
  • [F3]Represents shares withheld to satisfy withholding tax obligations upon the vesting of restricted stock grant.
  • [F4]1/12th of the shares underlying this option will vest in equal quarterly installments commencing one quarterly period after 12/31/2018.

Issuer

ZIOPHARM ONCOLOGY INC

CIK 0001107421

Entity typeother

Related Parties

1
  • filerCIK 0001641506

Filing Metadata

Form type
4
Filed
Jan 7, 7:00 PM ET
Accepted
Jan 8, 4:24 PM ET
Size
10.7 KB